Eli Lilly & Company has announced the US$1 million milestone payment to Aspen, a pharmaceutical manufacturer, as part of the joint collaboration on expanding access to medicines to treat multidrug-resistant tuberculosis (MDR-TB), according to Aspen Pharma.
The milestone is part of a Transfer of Technology agreement between Aspen and Lilly, initiated in 2003 under the umbrella of the Lilly MDR-TB Partnership, a global project to tackle the growing MDR-TB epidemic. Aspen is based in Johannesburg, South Africa.
The collaboration involved the transfer of Lilly’s drug manufacturing and packaging technology to enable Aspen to manufacture two essential anti-TB drugs. Lilly provided manufacturing know-how, access to technical experts, and other assistance to assure the quality and sustainability of the manufacturing processes.
The partnership with Aspen represents one of four similar partnerships Lilly holds with pharmaceutical manufacturers based in high burden countries where MDR-TB is most prevalent. These additional partnerships are between Lilly and SIA International (Russia), Shasun Chemicals and Drugs (India), and Hisun Pharmaceutical Co., Ltd (China).
.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment